Discovery and preclinical efficacy of HSG4112, a synthetic structural analog of glabridin, for the treatment of obesity

BACKGROUND: HSG4112 is a clinical-stage drug candidate for the treatment of obesity. Here, we report its discovery and preclinical efficacy. METHODS: In high-fat diet (HFD)-induced obese male C57BL/6J mice, we tested the weight loss effect of synthetic compounds derived from a structure–activity rel...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Leo Sungwong, Jo, In Geun, Kang, Ku Suk, Im, Jeong Ho, Kim, Jiyoung, Kim, Jinyoung, Chung, Jin Wook, Yoo, Sang-Ku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752758/
https://www.ncbi.nlm.nih.gov/pubmed/32943760
http://dx.doi.org/10.1038/s41366-020-00686-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752758/
https://www.ncbi.nlm.nih.gov/pubmed/32943760
http://dx.doi.org/10.1038/s41366-020-00686-1

Ejemplares similares